Evidence map›Paper›PMID 42830174›Full record

ArticleVirus research2026

Type I interferon mitigates ZIKV-induced neuroinflammation and cell death in the central nervous system.

Luciana Benevides, Herculano da Silva, Franciele Pioto, Thais da Silva Rigoni, Mariela Pires Cabral Piccin, Juliano de Paula Souza, Eurico Arruda, Vanessa Carregaro, João S Silva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Luciana BenevidesFiocruz-Bi-Institutional Translational Medicine Plataform, Ribeirão Preto, São Paulo, Brazil; Department of Biochemistry and Immunology, Ribeirão Preto Medical School University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Herculano da SilvaDepartment of Biochemistry and Immunology, Ribeirão Preto Medical School University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Franciele PiotoFiocruz-Bi-Institutional Translational Medicine Plataform, Ribeirão Preto, São Paulo, Brazil.
Thais da Silva RigoniFiocruz-Bi-Institutional Translational Medicine Plataform, Ribeirão Preto, São Paulo, Brazil.
Mariela Pires Cabral PiccinFiocruz-Bi-Institutional Translational Medicine Plataform, Ribeirão Preto, São Paulo, Brazil.
Juliano de Paula SouzaDepartment of Cell Biology and Virology Research Center, Ribeirão Preto Medical School University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Eurico ArrudaDepartment of Cell Biology and Virology Research Center, Ribeirão Preto Medical School University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Vanessa CarregaroDepartment of Biochemistry and Immunology, Ribeirão Preto Medical School University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
João S SilvaDepartment of Biochemistry and Immunology, Ribeirão Preto Medical School University of São Paulo, Ribeirão Preto, São Paulo, Brazil. Electronic address: jsdsilva@fmrp.usp.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zika virus (ZIKV) infection can cause severe neurological complications, particularly when antiviral immune responses are impaired. Here, we investigated how type I interferon (IFN-I) signaling influences the cellular inflammatory response and immunopathology in the central nervous system (CNS) during ZIKV infection. ZIKV infection induced early IFN-α and IFN-β expression in the CNS of wild-type (WT) mice. In contrast, mice lacking the IFN-I receptor (IFNAR

Indexed as

Cell deathIFN-I signalingNeuroinflammationZika virus

Identifiers

PMID42830174
PMCPMC13679374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.